Predictive Oncology (NASDAQ:AGPU) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Predictive Oncology (NASDAQ:AGPU) to a strong sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Predictive Oncology in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Predictive Oncology Stock Up 4.5%

Shares of Predictive Oncology stock opened at $5.85 on Friday. The firm has a fifty day simple moving average of $3.86. The company has a market cap of $32.41 million, a P/E ratio of -0.46 and a beta of 3.45. Predictive Oncology has a 52 week low of $1.03 and a 52 week high of $32.10.

Predictive Oncology (NASDAQ:AGPU) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.36) EPS for the quarter. The business had revenue of $0.04 million during the quarter.

About Predictive Oncology

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.